Intervacc AB (publ) (IVACC.ST)
SEK 0.95
(0.96%)
SEK 0.95
(0.96%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 21.68 Million SEK | 45.74% |
| 2022 | 14.87 Million SEK | -29.63% |
| 2021 | 21.14 Million SEK | 19.63% |
| 2020 | 17.67 Million SEK | 2.48% |
| 2019 | 17.24 Million SEK | 40.97% |
| 2018 | 12.23 Million SEK | -17.03% |
| 2017 | 14.74 Million SEK | -55.95% |
| 2016 | 33.47 Million SEK | 17.72% |
| 2015 | 28.43 Million SEK | -46.08% |
| 2014 | 52.73 Million SEK | 4143.19% |
| 2013 | 1.24 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 23.91 Million SEK | 30.65% |
| 2024 Q1 | 18.3 Million SEK | -15.58% |
| 2023 Q2 | 19.34 Million SEK | 5.81% |
| 2023 FY | 21.68 Million SEK | 45.74% |
| 2023 Q4 | 21.68 Million SEK | 19.3% |
| 2023 Q1 | 18.28 Million SEK | 22.9% |
| 2023 Q3 | 18.17 Million SEK | -6.06% |
| 2022 Q3 | 21.74 Million SEK | -2.36% |
| 2022 Q1 | 18.73 Million SEK | -11.36% |
| 2022 FY | 14.87 Million SEK | -29.63% |
| 2022 Q2 | 22.27 Million SEK | 18.86% |
| 2022 Q4 | 14.87 Million SEK | -31.6% |
| 2021 FY | 21.14 Million SEK | 19.63% |
| 2021 Q1 | 12.84 Million SEK | -27.31% |
| 2021 Q4 | 21.14 Million SEK | 27.06% |
| 2021 Q3 | 16.63 Million SEK | 6.26% |
| 2021 Q2 | 15.65 Million SEK | 21.89% |
| 2020 Q2 | 16.01 Million SEK | 5.38% |
| 2020 Q1 | 15.19 Million SEK | -11.89% |
| 2020 Q3 | 15.89 Million SEK | -0.75% |
| 2020 FY | 17.67 Million SEK | 2.48% |
| 2020 Q4 | 17.67 Million SEK | 11.21% |
| 2019 FY | 17.24 Million SEK | 40.97% |
| 2019 Q2 | 17.17 Million SEK | 73.43% |
| 2019 Q4 | 17.24 Million SEK | 9.41% |
| 2019 Q3 | 15.76 Million SEK | -8.2% |
| 2019 Q1 | 9.9 Million SEK | -19.07% |
| 2018 Q2 | 18.67 Million SEK | 132.56% |
| 2018 FY | 12.23 Million SEK | -17.03% |
| 2018 Q4 | 12.23 Million SEK | -0.78% |
| 2018 Q3 | 12.32 Million SEK | -33.99% |
| 2018 Q1 | 8.03 Million SEK | -45.53% |
| 2017 Q3 | 13.57 Million SEK | -63.12% |
| 2017 Q4 | 14.74 Million SEK | 8.65% |
| 2017 FY | 14.74 Million SEK | -55.95% |
| 2017 Q1 | 33.34 Million SEK | -0.39% |
| 2017 Q2 | 36.8 Million SEK | 10.37% |
| 2016 Q4 | 33.47 Million SEK | 0.0% |
| 2016 Q1 | - SEK | 0.0% |
| 2016 FY | 33.47 Million SEK | 17.72% |
| 2015 FY | 28.43 Million SEK | -46.08% |
| 2014 FY | 52.73 Million SEK | 4143.19% |
| 2013 FY | 1.24 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Alzinova AB (publ) | 9.33 Million SEK | -132.344% |
| Amniotics AB (publ) | 10.54 Million SEK | -105.556% |
| Asarina Pharma AB (publ) | 4.42 Million SEK | -389.833% |
| BioArctic AB (publ) | 139.5 Million SEK | 84.459% |
| Calliditas Therapeutics AB (publ) | 1.56 Billion SEK | 98.615% |
| Genovis AB (publ.) | 98.04 Million SEK | 77.888% |
| LIDDS AB (publ) | 3.75 Million SEK | -477.21% |
| Magle Chemoswed Holding AB (publ) | 123.97 Million SEK | 82.513% |
| OncoZenge AB (publ) | 1.69 Million SEK | -1176.045% |
| Saniona AB (publ) | 86.08 Million SEK | 74.815% |
| Simris Alg AB (publ) | 148.93 Million SEK | 85.444% |
| Vicore Pharma Holding AB (publ) | 40.85 Million SEK | 46.939% |
| AcouSort AB (publ) | 10.37 Million SEK | -108.903% |
| Active Biotech AB (publ) | 13.4 Million SEK | -61.791% |
| Camurus AB (publ) | 414.81 Million SEK | 94.774% |
| Cantargia AB (publ) | 54.97 Million SEK | 60.56% |
| Scandinavian ChemoTech AB (publ) | 3.83 Million SEK | -464.878% |
| Guard Therapeutics International AB (publ) | 18.49 Million SEK | -17.227% |
| Mendus AB (publ) | 51.22 Million SEK | 57.677% |
| Kancera AB (publ) | 17.97 Million SEK | -20.592% |
| Karolinska Development AB (publ) | 11.56 Million SEK | -87.397% |
| Lipum AB (publ) | 7.53 Million SEK | -187.609% |
| Lipigon Pharmaceuticals AB (publ) | 5.15 Million SEK | -320.318% |
| NextCell Pharma AB | 13.68 Million SEK | -58.375% |
| Xbrane Biopharma AB (publ) | 482.17 Million SEK | 95.504% |
| Xintela AB (publ) | 14.01 Million SEK | -54.691% |
| Ziccum AB (publ) | 6.38 Million SEK | -239.386% |
| Elicera Therapeutics AB (publ) | 13.77 Million SEK | -57.426% |
| Modus Therapeutics Holding AB (publ) | 2.35 Million SEK | -819.033% |
| Isofol Medical AB (publ) | 19.16 Million SEK | -13.129% |
| Xspray Pharma AB (publ) | 71.85 Million SEK | 69.826% |
| CombiGene AB (publ) | 4.15 Million SEK | -421.656% |
| Diamyd Medical AB (publ) | 71.11 Million SEK | 69.515% |
| Alligator Bioscience AB (publ) | 106.59 Million SEK | 79.661% |
| Sprint Bioscience AB (publ) | 34.6 Million SEK | 37.346% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 26.7 Million SEK | 18.826% |
| Corline Biomedical AB | 6.78 Million SEK | -219.34% |
| IRLAB Therapeutics AB (publ) | 61.35 Million SEK | 64.666% |
| Bio-Works Technologies AB (publ) | 16.11 Million SEK | -34.516% |
| Aptahem AB (publ) | 8.99 Million SEK | -140.947% |
| Infant Bacterial Therapeutics AB (publ) | 46.18 Million SEK | 53.053% |
| Fluicell AB (publ) | 8.91 Million SEK | -143.186% |
| Biovica International AB (publ) | 34.76 Million SEK | 37.642% |
| Spago Nanomedical AB (publ) | 11.66 Million SEK | -85.807% |
| Abliva AB (publ) | 16.78 Million SEK | -29.194% |
| Egetis Therapeutics AB (publ) | 214.6 Million SEK | 89.897% |
| 2cureX AB (publ) | 2.93 Million SEK | -638.671% |
| I-Tech AB | 16.2 Million SEK | -33.786% |
| Hansa Biopharma AB (publ) | 1.18 Billion SEK | 98.172% |
| Cyxone AB (publ) | 4.69 Million SEK | -361.866% |
| ExpreS2ion Biotech Holding AB (publ) | 13.32 Million SEK | -62.665% |
| Biosergen AB | 5.08 Million SEK | -326.352% |
| Nanologica AB (publ) | 79.32 Million SEK | 72.67% |
| SynAct Pharma AB | 51.83 Million SEK | 58.174% |
| Annexin Pharmaceuticals AB (publ) | 7.94 Million SEK | -172.739% |
| BioInvent International AB (publ) | 90.45 Million SEK | 76.032% |
| Stayble Therapeutics AB (publ) | 5.19 Million SEK | -317.329% |
| Oncopeptides AB (publ) | 181.59 Million SEK | 88.062% |
| Pila Pharma AB (publ) | 1.79 Million SEK | -1108.473% |
| Ascelia Pharma AB (publ) | 12.74 Million SEK | -70.119% |
| Diagonal Bio AB (publ) | 7.26 Million SEK | -198.623% |